Mazdutide vs Cagrilintide: Comparing Two Investigational Weight Loss Drugs

Mazdutide and cagrilintide are two investigational weight loss drugs that act on entirely different hormone pathways, and they have never been compared directly in a head-to-head clinical trial. Mazdutide is a dual GLP-1 and glucagon receptor agonist, while cagrilintide is a long-acting amylin analog. Any "which is better" answer therefore has to be pieced together from separate studies that used different doses, populations, and treatment durations.

What Is Mazdutide?

Mazdutide (development code IBI362) is a once-weekly injectable being developed by Innovent Biologics, under a license from Eli Lilly. It activates two receptors at once: GLP-1, which reduces appetite and slows stomach emptying, and glucagon, which may increase energy expenditure.

Quick facts about mazdutide:

• Class: dual GLP-1/glucagon receptor agonist
• Route: subcutaneous injection, once weekly
• Doses studied: 4 mg, 6 mg, and 9 mg
• Late-stage programs: GLORY-1 and related Phase 3 trials for weight management; DREAMS for type 2 diabetes
• US status: not FDA-approved for any indication

Most of the clinical data comes from trials run in China, where regulatory filings for weight management have been submitted. That matters when you compare results with drugs studied primarily in US and European populations, because baseline body weight and diet differ.

What Is Cagrilintide?

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-released with insulin after meals, and analogs of it reduce appetite and slow gastric emptying through a different mechanism than GLP-1 drugs.

Quick facts about cagrilintide:

• Class: amylin receptor agonist
• Route: subcutaneous injection, once weekly
• Doses studied: 0.6 mg to 4.5 mg as monotherapy; 2.4 mg in combination
• Main program: CagriSema, a fixed-dose combination of cagrilintide 2.4 mg plus semaglutide 2.4 mg
• US status: not FDA-approved for any indication

Cagrilintide as a standalone drug has largely been folded into combination development. Novo Nordisk has focused its late-stage effort on CagriSema rather than cagrilintide alone.

Mazdutide vs Cagrilintide: Side-by-Side Comparison

This table summarizes how the two drugs differ based on publicly reported trial data. Remember that these numbers come from different studies and are not directly comparable.

Feature	Mazdutide	Cagrilintide
Drug class	Dual GLP-1/glucagon agonist	Amylin analog
Developer	Innovent Biologics / Eli Lilly	Novo Nordisk
Dosing	Weekly injection, 4-9 mg	Weekly injection, 2.4 mg in combination
Lead Phase 3 program	GLORY (obesity), DREAMS (diabetes)	REDEFINE (obesity and diabetes, as CagriSema)
Reported weight loss	Roughly 12-15% at 48 weeks at 4-6 mg; about 18.6% at 48 weeks with 9 mg in an earlier trial	About 11.8% at 68 weeks as monotherapy 2.4 mg; about 22.7% at 68 weeks as part of CagriSema
Common side effects	Nausea, diarrhea, vomiting, upper respiratory infection	Nausea, vomiting, diarrhea, injection site reactions
FDA approval	No	No

Weight Loss Results: What the Trials Actually Show

Reported weight loss is the headline number most people look for, and it is also where comparisons get slippery.

• In the Phase 3 GLORY-1 trial, adults with obesity or overweight receiving mazdutide lost roughly 12% to 15% of body weight at 48 weeks, depending on dose, compared with a small change on placebo.
• In an earlier Phase 2 trial, mazdutide 9 mg produced about 18.6% weight loss at 48 weeks in a smaller group of participants.
• In the REDEFINE 1 trial, cagrilintide 2.4 mg alone produced about 11.8% weight loss at 68 weeks, while the combination CagriSema reached about 22.7%.

Cross-trial comparisons of weight loss percentages are unreliable. Trial length, baseline BMI, background diet counseling, and how missing data were handled all shift the final number, sometimes by several percentage points. Mazdutide and cagrilintide have never been tested against each other in a head-to-head clinical trial.

Dosing, Availability, and Cost

Neither drug can be prescribed at a US pharmacy today. Both are given as once-weekly subcutaneous injections that typically require dose escalation over several weeks to limit gastrointestinal side effects.

Because neither product is on the market, there is no official price. Anything sold online as "mazdutide" or "cagrilintide" is unregulated, unverified for purity, and not intended for human use. Those products are frequently marketed as research chemicals, and dosing them yourself carries real risk of contamination, incorrect strength, and serious harm.

If and when either drug reaches the market, US pricing will likely resemble that of other brand-name incretin therapies, which often run well over $1,000 per month before insurance or discount programs. People often ask how mazdutide vs semaglutide shakes out on cost, and the honest answer is that no one knows yet because mazdutide has no US list price.

Side Effects and Safety Considerations

Gastrointestinal effects dominate the side effect profile of both drugs. Nausea, vomiting, diarrhea, and constipation are the most common complaints, and they usually ease as the body adjusts to a stable dose.

Broader class concerns for GLP-1-based therapies include gallbladder disease, pancreatitis, increased resting heart rate, and rare cases of gastroparesis. Amylin analogs can also cause injection site reactions and, in some studies, mild hypoglycemia when combined with insulin or sulfonylureas.

Both drug classes are generally not recommended during pregnancy, and anyone with a personal or family history of medullary thyroid carcinoma or MEN2 should discuss alternatives with a clinician. Only a licensed healthcare professional can evaluate whether an investigational or approved weight loss drug is appropriate for a specific person.

How They Stack Up Against Other Weight Loss Drugs

Mazdutide and cagrilintide sit inside a crowded field of injectable therapies, and several comparisons are worth reading alongside this one.

• A separate cagrilintide vs tirzepatide comparison is useful because tirzepatide is an approved dual GLP-1/GIP agonist with strong Phase 3 results.
• The cagrilintide vs retatrutide question comes up often, since retatrutide is an investigational triple agonist that has posted weight loss above 24% in mid-stage trials.
• Another once-weekly amylin candidate, petrelintide, is being watched closely; petrelintide vs cagrilintide discussions tend to focus on tolerability and gastrointestinal burden.
• Lilly's amylin program is also advancing, and eloralintide vs cagrilintide is a pairing researchers will likely study in the coming years.

Each of these drugs targets a different combination of receptors, which helps explain why their efficacy and side effect profiles diverge.

Key Takeaways

• Mazdutide is a dual GLP-1/glucagon agonist, and cagrilintide is an amylin analog.
• No head-to-head trial has directly compared mazdutide and cagrilintide.
• Cagrilintide's most impressive numbers come from its combination with semaglutide, not from monotherapy.
• Neither mazdutide nor cagrilintide is FDA-approved for weight loss in the United States.

For now, anyone seeking treatment should talk with a healthcare provider about approved options rather than sourcing investigational peptides online.

COMMON QUESTIONS

Frequently Asked Questions

Which is better for weight loss, mazdutide or cagrilintide?

There is no head-to-head trial, so no one can say which is better. In separate studies, mazdutide produced roughly 12% to 15% weight loss at 48 weeks at 4-6 mg, while cagrilintide monotherapy produced about 11.8% at 68 weeks. The combination of cagrilintide plus semaglutide has shown about 22.7% weight loss, but that is a two-drug product, not cagrilintide alone.

Is cagrilintide FDA-approved or available in the US?

No. Cagrilintide is not FDA-approved for any indication and cannot be prescribed at a US pharmacy. Novo Nordisk has focused on the combination product CagriSema, which pairs cagrilintide with semaglutide. Products sold online as cagrilintide are unregulated and not intended for human use.

Are mazdutide and cagrilintide safe?

Both drugs have shown acceptable safety profiles in clinical trials, with nausea, vomiting, and diarrhea as the most common side effects. Class-level concerns for GLP-1 and amylin therapies include gallbladder disease, pancreatitis, and injection site reactions. Anyone considering these drugs should consult a healthcare professional rather than self-dosing with research-grade peptides.